NCT07011004View on ClinicalTrials.gov

A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia

PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 30, 2025

Primary Completion Date

May 31, 2028

Study Completion Date

May 31, 2028

Conditions
Acute Myeloid Leukemia RefractoryAcute Myeloid Leukemia, in Relapse
Interventions
BIOLOGICAL

Cytokine Induced Memory-Like Natural Killer Cells

Subjects will receive subcutaneous recombinant human IL-2 (rh-IL2) every other day x 6 doses beginning on day 0 via subcutaneous injection.

BIOLOGICAL

Atezolizumb

Single dose of Atezolizumab IV over 60 minutes IV.

BIOLOGICAL

CIML-NK cell therapy

CIML-NK cell therapy as an intravenous (IV) infusion

Trial Locations (7)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

10604

RECRUITING

Memorial Sloan Kettering West Harrison (Limited Protocol Activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (Limited Protocol Activites), Rockville Centre

11725

RECRUITING

Memorial Sloan Kettering Suffolk - Commack (Limited protocol activities), Commack

07920

RECRUITING

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER